- Home
- SRL vs LPTX Comparison
SRL vs LPTX Comparison
Compare SRL & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRL
- LPTX
- Stock Information
- Founded
- SRL 2017
- LPTX 2011
- Country
- SRL China
- LPTX United States
- Employees
- SRL N/A
- LPTX N/A
- Industry
- SRL Professional Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRL Consumer Discretionary
- LPTX Health Care
- Exchange
- SRL Nasdaq
- LPTX Nasdaq
- Market Cap
- SRL 121.2M
- LPTX 117.1M
- IPO Year
- SRL N/A
- LPTX N/A
- Fundamental
- Price
- SRL $7.93
- LPTX $2.96
- Analyst Decision
- SRL
- LPTX Strong Buy
- Analyst Count
- SRL 0
- LPTX 5
- Target Price
- SRL N/A
- LPTX $10.40
- AVG Volume (30 Days)
- SRL 8.1K
- LPTX 522.5K
- Earning Date
- SRL 12-09-2024
- LPTX 11-13-2024
- Dividend Yield
- SRL N/A
- LPTX N/A
- EPS Growth
- SRL N/A
- LPTX N/A
- EPS
- SRL 0.07
- LPTX N/A
- Revenue
- SRL $41,604,386.00
- LPTX N/A
- Revenue This Year
- SRL N/A
- LPTX N/A
- Revenue Next Year
- SRL N/A
- LPTX N/A
- P/E Ratio
- SRL $115.04
- LPTX N/A
- Revenue Growth
- SRL N/A
- LPTX N/A
- 52 Week Low
- SRL $4.09
- LPTX $1.34
- 52 Week High
- SRL $8.59
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- SRL 40.80
- LPTX 44.64
- Support Level
- SRL $7.65
- LPTX $2.95
- Resistance Level
- SRL $8.13
- LPTX $3.61
- Average True Range (ATR)
- SRL 0.27
- LPTX 0.42
- MACD
- SRL -0.03
- LPTX -0.11
- Stochastic Oscillator
- SRL 0.00
- LPTX 2.72
About SRL Scully Royalty Ltd.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .